Cited by

• Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study.

  Marcocci C, Bartalena L, Bogazzi F, Bruno-Bossio G, Lepri A, Pinchera A. Marcocci C, et al. J Endocrinol Invest. 1991 Nov;14(10):853-60. doi: 10.1007/BF03347943. J Endocrinol Invest. 1991. PMID: 1802923 Clinical Trial.
• Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.

  Smith TJ, Janssen JAMJL. Smith TJ, et al. Endocr Rev. 2019 Feb 1;40(1):236-267. doi: 10.1210/er.2018-00066. Endocr Rev. 2019. PMID: 30215690 Free PMC article. Review.
• Early detection of P-VEP and PERG changes in ophthalmic Graves' disease.

  Spadea L, Bianco G, Dragani T, Balestrazzi E. Spadea L, et al. Graefes Arch Clin Exp Ophthalmol. 1997 Aug;235(8):501-5. doi: 10.1007/BF00947007. Graefes Arch Clin Exp Ophthalmol. 1997. PMID: 9285219
• Thyroid eye disease: towards an evidence base for treatment in the 21st century.

  Gillespie EF, Smith TJ, Douglas RS. Gillespie EF, et al. Curr Neurol Neurosci Rep. 2012 Jun;12(3):318-24. doi: 10.1007/s11910-012-0256-9. Curr Neurol Neurosci Rep. 2012. PMID: 22354545 Free PMC article. Review.
• [Endocrine ophthalmopathy in Graves disease during antithyroid drug therapy (author's transl)].

  Wuttke H, Schlieter D, Krück F. Wuttke H, et al. Klin Wochenschr. 1979 Jan 15;57(2):69-74. doi: 10.1007/BF01491337. Klin Wochenschr. 1979. PMID: 84095 German. No abstract available.